CCR2 and neoplasm: To assess whether the tumor-associated inflammatory monocytes (TAIMs) could internalize BG34-200-AF647 after IV administration, we examined the frequency of BG34-200-AF647+ cells in the circulating CD11b+CCR2+ cells and found that more than 30% cells were CD11b+CCR2+BG34-200-AF647+ (Figure 3C).